You are here

  • Home
  • Archive
  • Volume 12, Issue 9
  • Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma

Citation Tools

Article menu

Download PDFPDF

Gastroenterology and hepatology
Protocol
Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Zhang B, Yue J, Shi X, et al
Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
BMJ Open 2022;12:e060955. doi: 10.1136/bmjopen-2022-060955